Cargando…
The Absorb bioresorbable vascular scaffold in real-world practice: long-term follow-up of the AMC Single Centre Real World PCI Registry
BACKGROUND: Bioresorbable scaffolds have been introduced to overcome the shortcomings of drug-eluting stents. Higher rates of device thrombosis, however, have been reported up to 3 years after implantation of the Absorb bioresorbable vascular scaffold (BVS). In the current article, we therefore repo...
Autores principales: | Tijssen, R. Y. G., Annink, M. E., Kraak, R. P., Koch, K. T., Baan Jr, J., Vis, M. M., Piek, J. J., Henriques, J. P. S., de Winter, R. J., Beijk, M. A. M., Wykrzykowska, J. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bohn Stafleu van Loghum
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052095/ https://www.ncbi.nlm.nih.gov/pubmed/31953774 http://dx.doi.org/10.1007/s12471-019-01362-4 |
Ejemplares similares
-
Three‐year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus‐eluting stent in routine PCI in patients with diabetes mellitus—AIDA sub‐study
por: Kerkmeijer, Laura S.M., et al.
Publicado: (2020) -
Real-life use of left ventricular circulatory support with Impella in
cardiogenic shock after acute myocardial infarction: 12 years AMC
experience
por: Ouweneel, Dagmar M, et al.
Publicado: (2018) -
Mid-term and long-term safety and efficacy of bioresorbable vascular scaffolds versus metallic everolimus-eluting stents in coronary artery disease: A weighted meta-analysis of seven randomised controlled trials including 5577 patients
por: Elias, J., et al.
Publicado: (2017) -
Pre-PCI versus immediate post-PCI Impella initiation in acute myocardial infarction complicated by cardiogenic shock
por: Hemradj, Veemal V., et al.
Publicado: (2020) -
Early mobilisation after transfemoral transcatheter aortic valve implantation: results of the MobiTAVI trial
por: Vendrik, J., et al.
Publicado: (2020)